Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K0YX
|
||||
| Former ID |
DNC009966
|
||||
| Drug Name |
5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H17NO3
|
||||
| Canonical SMILES |
C1=CC(=CC=C1CCC(CC(=O)O)O)C2=CC=C(C=C2)C#N
|
||||
| InChI |
1S/C18H17NO3/c19-12-14-3-8-16(9-4-14)15-6-1-13(2-7-15)5-10-17(20)11-18(21)22/h1-4,6-9,17,20H,5,10-11H2,(H,21,22)
|
||||
| InChIKey |
YDAZWMGCTBJQEO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Collagenase 3 | Target Info | Inhibitor | [1] | |
| MMP-12 | Target Info | Inhibitor | [1] | ||
| NetPath Pathway | IL1 Signaling PathwayNetPath_13:IL1 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Assembly of collagen fibrils and other multimeric structuresR-HSA-1442490:Collagen degradation | |||||
| WikiPathways | Endochondral Ossification | ||||
| Activation of Matrix Metalloproteinases | |||||
| Oncostatin M Signaling Pathway | |||||
| AGE/RAGE pathway | |||||
| Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway | |||||
| Degradation of collagen | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. Epub 2009 Aug 6.The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.